Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318562 · ClinicalTrials.gov registry record · Phase 2
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
A Phase 2 study, sponsored by Effector Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03318562 is a Phase 2 study that was terminated before completion, run by Effector Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT03318562, a Phase 2 study, was terminated before completion, sponsored by Effector Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.
Interventions
- DRUG eFT508
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2019-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318562
The ClinicalTrials.gov registry entry for NCT03318562 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eFT508 is the first listed.
NCT03318562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318562 about?
NCT03318562 is a clinical study titled "A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC". This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disea...
What is the current status of trial NCT03318562?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-11-21. Estimated completion is 2019-01-22.
What interventions are being tested in trial NCT03318562?
The interventions under investigation include: eFT508 (DRUG).
Who is sponsoring clinical trial NCT03318562?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.